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Abstract 
A single-hit model for dominantly heritable tumor syn­
dromes Is presented. This model suggests that: 1) 
During embryogenesis replication potential may nor­
mally be restricted by Interaction of cell line-specific 
maturation factors with a finite number of surface re­
ceptors of each cell of the appropriately matched line. 
2) In dominantly heritable multlfocal tumor prone con­
ditions, embryonic "rest" cells may result from chance 
Insufficiencies of functional cell surface receptors at 
the time of peak concentration of the appropriate em­
bryonic maturation factor. 3) Congenital unlfocal non­
heritable embryonic "rests" could arise as a conse­
quence of rare chance failure of a normal, yet fallible, 
system. 4) Embryonal dominantly heritable tumors are 
of monoclonal derivation. 
Introduction 
Cancers were recently classified thus: Class 1: Hereditary 
neoplastic conditions arising entirely independently of en­
vironmental factors; Class II: Those for which the patho­
genesis can be accounted for on the basis of environ­
mental influences alone; Class Ill: Those which occur as 
a result of a combination of environmental and genetic 
influences; and Class IV: "Background" cancers for which 
no role to either environment or genetics can be estab­
lished (Knudson, 1980). Class I tumors inherited as Men­
delian autosomal dominant disorders may also arise as 
Class IV sporadic, non-heritable, solitary primary neo­
plasms. For such tumors the dominantly inherited form is 
characterized by a high risk for a specific kind of tumor 
presenting as multiple primary tumors (Knudson, 1974). 
Examples of these disorders are: retinoblastoma, the 
phakomatoses, polyposis coli, nevoid basal cell carci­
noma syndrome, malignant melanoma, multiple endo­
crine neoplasia syndromes, familial breast cancer, leu­
kemias, lymphomas, brain tumors, Wilms' tumor, 
neuroblastoma, pheochromocytoma, and chemodec­
toma (Knudson, 1973, 1978, 1980; Knudson and Strongs, 
1972). 
Using retinoblastoma as a paradigm of such Class 1/Ciass 
IV tumors, Knudson (1971, 1978) developed an hypoth­
esis that the Class I neoplasias arise as a result of a 
germinal mutation followed by a single somatic mutation 
at each primary tumor site. Furthermore, according to 
Knudson the Class IV tumors resulted as a consequence 
of two separate, sequential somatic mutations, the first of 
these being a rare event which compensates for the ab­
sence of the germinal mutation. In these studies, data 
collected from retinoblastoma kindreds confirmed that 
carriers of the retinoblastoma gene are usually afflicted 
with one or more tumors in each eye but may escape with 
only a single unilateral tumor or sometimes even with no 
lesion at all. Knudson concluded that the precise number 
of primary tumors acquired by a gene carrier was purely 
a matter of chance. Hence his "two-hit" model for the 
origin of cancer rested, at least in part, on the implicit 
assumption that "chance" is synonymous with additional 
mutation (Knudson, 1971, 1978). Other models have also 
been proposed to account for the penetrance patterns of 
the retinoblastoma gene. For instance, Matsunaga (1978) 
proposed that retinoblastoma gene manifestation is a 
function of epigenetically inherited "host resistance," while 
Carlson and Desnick (1979) suggested multiple allelism 
and tissue mosaicism as the cause of variability of pe­
netrance and expressivity in familial cases of retinoblas­
toma. But these latter hypotheses were not put forward 
by their authors to be universally applied and will not be 
discussed further here. Instead, a new model will be pre­
sented. This model potentially accounts for dominantly 
inherited tumors on the basis of single germinal mutations 
and may also provide insight into the pathogenesis of 
sporadic unifocal embryonal tumors. The proposed model 
is developed from the hypothesis that sequential cellular 
maturation (i.e. , permanent restriction of replication po­
tential) is directed at least in part by a complex network 
of embryonic inter-tissue coded chemical messengers 
which function as maturation hormones. 
A Single Hit Model 
Mintz and her coworkers (1977) have provided evidence 
in support of the concept that cellular maturation involves 
extrinsic signaling during embryogenesis. She took mouse 
malignant teratocarcinoma cells and found that upon their 
injection into early mouse embryos at the blastocyst stage, 
the cells became integrated into the developing embryo. 
In the mosaic mice that were formed, tumor-derived cells 
gave rise to the full range of normal functional somatic 
tissues and also to normal germ cells, implying some form 
of extrinsic regulation. 
If extrinsic maturation signals exist then cell receptors for 
those signals are likely to exist as well. Indeed Zelkowitz 
and Stambouly (1980) recently presented evidence that 
neurofibromatosis is associated with a membrane defect 
which is reflected by a fifty percent diminution of epider­
mal growth factor (EGF) binding by fibroblasts taken from 
affected individuals. They proposed that an embryonic 
membrane defect may underlie the pathogenesis of this 
disease. Moreover, as mentioned above, as each type of 
dominant embryonal tumor-prone disorder is associated 
with a specific kind of tumor, it may be anticipated that 
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maturation signals include a system of cell line-specific 
hormones which interact with cell line-specific receptors. 
It is proposed that in each disease the underlying lesion 
is in a gene which encodes for a protein involved in some 
part of the maturation signal-receptor interaction. Fur­
thermore, it is expected that on the average, during any 
growth cycle, a heterozygous cell's pool of gene-product, 
which encodes receptor specificity, is about half normal 
and half mutant with respect to the altered locus. In ad­
dition, it is also likely that individual transcripts are se­
lected randomly when removed from the nuclear pool and 
transported to the cytoplasm to serve as mRNA templates. 
Therefore, during any single embryonic cell growth-cycle 
of a heterozygote the numbers of normal functional re­
ceptors per cell would be distributed among the cells of 
the affected line according to a Gaussian distribution. As 
a result there would be a finite random number of variably 
located cells which utilize insufficient normal RNA to sat­
isfy a minimum need for functional cell surface receptors 
during the period when maturation normally occurs. Thus, 
such temporarily "pseudohomozygous" cells would fail to 
mature and consequently would be left behind as em­
bryonic "rests" - foci of potential neoplasia. Finally, neither 
the peak maturation hormone concentration nor the num­
bers and distribution of pseudohomozygous cells can be 
expected to be exactly reproduced from one individual 
embryo to another, hence chance variations of pane­
trance of single mutated genes. 
The existence of such a system of cell line-specific growth 
maturation hormones and receptors would also account 
for, at least, a portion of the subgroup of Class IV "back­
ground" tumors which are of embryonic "rest" origin. This 
follows from the fact that interactions between hormones 
and their receptors are random chance events. Therefore, 
the probability of the occurrence of any one such inter­
action is a function of finitely .limited variables - the hor­
mone concentration, the number of receptors per embry­
onic cell, and the reaction time available. Thus, this 
probability is in itself finite, and where a minimum finite 
number of such interactions per cell is required to ensure 
transition from the embryonic state to the mature state, 
failure-free maturation of an infinite number of cells is an 
impossibility. The probability of "background" failure of a 
cell's maturation (P1") may approach but can never equal 
zero (Figure 1 ). Stated more succinctly - there cannot be 
a one hundred percent guarantee during embryogenesis, 
even with genetically normal individuals. P," can be re­
duced by increasing the number of receptors per cell, 
but at a saturating hormone concentration, where most 
cells have synthesized at least the minimum number of 
receptors that are required to react, further increases in 
number of receptors per cell will yield a rapidly diminish­
ing return in terms of reduction of P1". However, since 
failure of reception of such a critical message by even a 





RECEPTORS-MEAN NUMBER PER CELL 
Figure 1. The Fallibility of Embryonic Maturation Hormone-Receptor 
Systems. This plot illustrates the concept that the probability of suc­
cessful maturation of homozygous normal embryonic cells is finitely 
limited. P1" = probability of background failure. 
and lead to the early demise of the entire organism, such 
a relatively uneconomical defense would be of survival 
value as it helps to further reduce the incidence of such 
catastrophes. 
This one-hit model, in addition to accounting for variation 
in penetrance of cancer pre-disposing states, also gives 
a theoretical basis for the wide variation of the expression 
of these conditions. Retention of the embryonic state - as 
a result of failure to interact with maturation factors - may 
be viewed as a necessary but probably insufficient con­
dition for neoplastic replication of cells to occur. Additional 
factors such as growth space and non-readily available 
specific nutrients and hormones may be auxilliary require­
ments for their development into symptomatic neoplasias. 
For instance, in neurofibromatosis the principal lesions 
are tumors of supporting elements of the nervous system 
such as neurofibromas, Schwannomas, and menin­
giomas. This condition is characterized by long periods 
of slow progression or even total quiescence and exac­
erbations during or following puberty or pregnancy (Con­
ale and Bebin, 1972; Crowe et al., 1956). The progression 
of this disease is believed to depend on special hormonal 
conditions (Mobley et al., 1977). On the other hand, "rest" 
cell neoplasias which are malignant may be seen either 
as arising from a cell-line which normally undergoes mat­
uration in a relatively undifferentiated state or else as re­
sulting from dedifferentiation of a pre-existing benign dif­
ferentiated "rest" tumor. Retinoblastoma (Apt and Gaffney, 
1977) and neurofibrosarcoma are examples of the former 
and latter, respectively. 
Are Embryonal Tumors of Monoclonal or Polyclonal 
Origin? 
According to the single-hit model, individual embryonal 
tumors are derived from single cells, i.e., are of mono­
clonal origin. The major approach to determining whether 
embryonal tumors are of monoclonal or polyclonal origin 
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has been through studies of tumors taken from affected 
females who are coincidently heterozygous for an X-chro­
mosomal marker. Since in each of any female's somatic 
cells one of. the two X-chromosomes is randomly selected 
for inactivation during the process of Lyonization, mon­
oclonal origin of a tumor can be demonstrated by showing 
that all the tumor cells have either one or the other of the 
X-chromosomal markers. However, the prevalent notion 
that the converse (presence of both markers implies poly­
clonal origin) is also true may be misleading. Thus, for 
example, hereditary neurofibromas were subjected to this 
kind of test by Fialkow and colleagues (1971 ). They found 
that both X-chromosomal markers were expressed in neu­
rofibromas from their test subjects and suggested that 
neurofibromas are of polyclonal origin. However, it is 
questionable to apply this test to neurofibromas as both 
light and electron microscopy have shown that neurofi­
bromas contain both Schwann cells and fibroblasts (Es­
courolle and Poirier, 1978). In addition, Fialkow and his 
collaborators add the caveat that the validity of the poly­
clonal interpretation may be incorrect if an initially affected 
monoclone affects the growth patterns of adjacent cells. 
Thus, it should also be noted that normal mature Schwann 
cells adjacent to a site of nerve injury are known to undergo 
limited reactive replication in attempts to repair the injury 
(Hall, 1978). Consequently, even in tumors which are pure 
Schwann cell outgrowths (Schwannomas), X-chromo­
somal marker analysis is liable to yield misleading results 
since inappropriate replication of an original embryonic 
"rest" cell may lead to limited replication of neighboring 
normal Schwann cells. Indeed, presence of two inter­
mixed tissue types, dense fibrillary (Antonini A) and loose 
reticulated (Antonini B) (Escourelle and Poirier, 1978), hints 
that such a mechanism may in fact be operative in 
Schwan no mas. 
The present model predicts that one of the two tissue 
types of a Schwannoma should be of monoclonal origin. 
In fact, certain dominantly inherited embryonal tumors have 
already been shown to be of monoclonal origin. For in­
stance, Baylin and his coworkers (1976) found that in­
herited pheochromocytoma and medullary thyroid car­
cinoma have single X-chromosomes in appropriate 
heterozygous test subjects. In addition, where an individ­
ual has multiple primary medullary thyroid carcinomas, 
they are generated as separate monoclones (Baylin et al., 
1978) as predicted by the single-hit model. 
Differences Between the Single Hit Model and 
Knudson's Two Hit Model 
The phenomenon of spontaneous regression of dissem­
inated neoplasia can be explained in terms of the single­
hit model by an unscheduled, but timely, burst of synthe­
sis of maturation factor. However, because of the obvious 
difficulty in reconciling spontaneous regression of dis-
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seminated malignancy with the tandem two mutation 
scheme, Knudson and Meadows (1980) recently sug­
gested that certain embryonal tumors may be products 
of single rather than double "hits". They then proceeded 
to assign various embryonal tumors to either one or the 
other of these two categories. Their "one-hit" list included 
regressing neuroblastoma and neurofibromas while non­
regressing neuroblastoma and neurofibrosarcoma were 
placed on the "two-hit" list. However, as mentioned above, 
since Knudson visualized a need for a second mutation 
in order to account for variation in penetrance of a major 
tumor-promoting gene, it remains unclear how Knudson 
and Meadows, having placed neurofibromas on a one-hit 
list, propose to account for the divergence of penetrance 
of neurofibromas in affected monozygous siblings (Vaughn 
et al., 1981). 
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